Alterome Therapeutics, Inc.

Biosplice Therapeutics, Inc.

Eric Anthony Murphy

Xuefeng Zhu

Michael D Bartberger

Elena V Dneprovskaia

John Hood

Vishal Deshmukh

Provided herein are inhibitors of KRAS, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the KRAS inhibitory compounds for the treatment of diseases or disorders.

Substituted pyrido [4,3-d]pyrimidines as KRAS modulators

Provided herein are inhibitors of AKT1, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the AKT1 inhibitory compounds for the treatment of disease.

AKT1 modulators

This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

Growing community of inventors

San Marcos, CA, United States of America

Eric Anthony Murphy